Literature DB >> 7438073

Detection of early and delayed antitumor effects following curative adoptive chemoimmunotherapy of established leukemia.

P D Greenberg, M A Cheever, A Fefer.   

Abstract

Advanced disseminated leukemia can be successfully eradicated by treatment with a combination of noncurative nonlethal chemotherapy plus adoptively transferred immune cells. The time course of tumor elimination following such therapy was examined by bioassay for tumor of peripheral blood and spleen cells from treated mice. Curative treatment with adoptive chemoimmunotherapy did not immediately eliminate all leukemia. Bioassay of cells from treated mice, rather, demonstrated that, following the initial tumor lysis mediated by the chemotherapy and immune cells, a period of tumor regrowth lasting several weeks preceded ultimate tumor eradication. This transient tumor regrowth detectable by bioassay never became clinically evident in the treated mice. However, immunosuppression of mice two weeks after treatment with adoptive chemoimmunotherapy resulted in recurrence of lethal tumor. The results suggest that tumor elimination following curative adoptive chemoimmunotherapy is biphasic and that the efficacy of therapy may be subject to positive and/or negative influences over a prolonged time period.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 7438073

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  17 in total

Review 1.  Exploitation of the propulsive force of chemotherapy for improving the response to cancer immunotherapy.

Authors:  Enrico Proietti; Federica Moschella; Imerio Capone; Filippo Belardelli
Journal:  Mol Oncol       Date:  2011-12-03       Impact factor: 6.603

2.  Abrogating Cbl-b in effector CD8(+) T cells improves the efficacy of adoptive therapy of leukemia in mice.

Authors:  Ingunn M Stromnes; Joseph N Blattman; Xiaoxia Tan; Sara Jeevanjee; Hua Gu; Philip D Greenberg
Journal:  J Clin Invest       Date:  2010-09-20       Impact factor: 14.808

3.  Long-term immunological memory in the resistance of rats to transplanted intracerebral 9L gliosarcoma (9LGS) following subcutaneous immunization with 9LGS cells.

Authors:  H M Smilowitz; D D Joel; D N Slatkin; P L Micca; M M Nawrocky; K Youngs; W Tu; J A Coderre
Journal:  J Neurooncol       Date:  2000       Impact factor: 4.130

Review 4.  Specific adoptive immunotherapy: experimental basis and future potential.

Authors:  P D Greenberg; M A Cheever; A Fefer
Journal:  Surv Immunol Res       Date:  1982

5.  Adoptive chemoimmunotherapy of a syngeneic murine lymphoma with long-term lymphoid cell lines expanded in T cell growth factor.

Authors:  T J Eberlein; M Rosenstein; P Spiess; R Wesley; S A Rosenberg
Journal:  Cancer Immunol Immunother       Date:  1982       Impact factor: 6.968

Review 6.  Re-adapting T cells for cancer therapy: from mouse models to clinical trials.

Authors:  Ingunn M Stromnes; Thomas M Schmitt; Aude G Chapuis; Sunil R Hingorani; Philip D Greenberg
Journal:  Immunol Rev       Date:  2014-01       Impact factor: 12.988

7.  Rescue of anti-influenza A virus cytotoxic T-lymphocyte responses in chemotherapy-suppressed mice.

Authors:  V J Merluzzi; K Welte; R H Mertelsmann; L Souza; T Boone; K Last-Barney
Journal:  J Virol       Date:  1984-07       Impact factor: 5.103

8.  Augmentation of the anti-tumor therapeutic efficacy of long-term cultured T lymphocytes by in vivo administration of purified interleukin 2.

Authors:  M A Cheever; P D Greenberg; A Fefer; S Gillis
Journal:  J Exp Med       Date:  1982-04-01       Impact factor: 14.307

9.  Increase in the effectiveness of melphalan therapy with progression of MOPC-315 plasmacytoma tumor growth.

Authors:  S Ben-Efraim; R C Bocian; M B Mokyr; S Dray
Journal:  Cancer Immunol Immunother       Date:  1983       Impact factor: 6.968

10.  Protection against syngeneic lymphoma by a long-lived cytotoxic T-cell clone.

Authors:  M O Dailey; E Pillemer; I L Weissman
Journal:  Proc Natl Acad Sci U S A       Date:  1982-09       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.